Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 12/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1781098 | 0.80 | ADORA2B (0.54) | ADORA2BADORA2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL14267750 | 0.76 | ADORA2A (0.61) | ADORA2BADORA2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL5332346 | 0.75 | ADORA2B (0.63) | ADORA2BADORA2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL1944639 | 0.72 | ADORA2B (0.75) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL14267722 | 0.72 | ADORA2B (0.71) | ADORA2BADORA2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL661108 | 0.72 | ADORA2B (1.00) | ADORA2BADORA2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL5035079 | 0.70 | ADORA1 (0.52) | ADORA2BADORA2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL5035043 | 0.70 | ADORA2B (0.52) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL8872884 | 0.70 | ADORA2B (0.65) | ADORA2BADORA2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL2854150 | 0.69 | ADORA2B (1.00) | ADORA2BADORA2AADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011528364-A | — | — | 2011-11-17 | — | — | JP | claimed |
| US-20110118276-A1 | METHODS OF TREATING ATHEROSCLEROSIS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT INC | 2011-05-19 | — | — | US | claimed |
| EP-2306838-A1 | METHODS OF TREATING ATHEROSCLEROSIS | King Pharmaceuticals Research and Development Inc. (US) | 2011-04-13 | — | — | EP | claimed |
| WO-2010009194-A1 | METHODS OF TREATING ATHEROSCLEROSIS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2010-01-21 | — | — | WO | claimed |
| US-7335655-B2 | 8-heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2008-02-26 | — | — | US | claimed |
| US-7205403-B2 | 8-Heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2007-04-17 | — | — | US | claimed |
| US-20060142309-A1 | 8-Heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2006-06-29 | — | — | US | claimed |
| US-20030207879-A1 | 8-Heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2003-11-06 | — | — | US | claimed |
| US-20110118276-A1 | METHODS OF TREATING ATHEROSCLEROSIS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT INC | 2011-05-19 | — | — | US | disclosed |
| EP-2306838-A1 | METHODS OF TREATING ATHEROSCLEROSIS | King Pharmaceuticals Research and Development Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010009194-A1 | METHODS OF TREATING ATHEROSCLEROSIS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
| US-7335655-B2 | 8-heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20060142309-A1 | 8-Heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118276-A1 | METHODS OF TREATING ATHEROSCLEROSIS | ADORA2B, ADORA2A, ADORA3 | ADORA2B 1/4885ADORA2A 2/4885KDM4E 4444/4885 |
| US-20030207879-A1 | 8-Heteroaryl xanthine adenosine A2B receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885KDM4E 3848/4885 |
| US-20060142309-A1 | 8-Heteroaryl xanthine adenosine A2B receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885KDM4E 4172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.